FDA Approves Expanded Use of GE HealthCare's Vizamyl for Enhanced Alzheimer's Diagnosis and Monitoring
I'm PortAI, I can summarize articles.
GE HealthCare Technologies Inc. announced that the FDA has approved an updated label for its PET imaging agent VizamylTM, enhancing its use for beta-amyloid detection in Alzheimer's diagnosis and monitoring. The approval allows for quantitative analysis and removes previous limitations on monitoring patient response to anti-amyloid therapy, improving personalized care for patients. This marks a significant milestone for GE HealthCare’s Pharmaceutical Diagnostics division, supporting better healthcare outcomes.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments